Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.74 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.63 |
| ▸ | GAK | O14976 | 3/20 | 0.63 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.63 |
| ▸ | BUB1 | O43683 | 2/20 | 0.63 |
| ▸ | STK10 | O94804 | 2/20 | 0.63 |
| ▸ | MAP3K1 | Q13233 | 2/20 | 0.63 |
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 0.63 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.63 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.63 |
| ▸ | PLK4 | O00444 | 1/20 | 0.63 |
| ▸ | CIT | O14578 | 1/20 | 0.63 |
| ▸ | AURKA | O14965 | 1/20 | 0.63 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.63 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.63 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.63 |
| ▸ | KDM1A | O60341 | 1/20 | 0.63 |
| ▸ | JAK2 | O60674 | 1/20 | 0.63 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.63 |
| ▸ | STK17B | O94768 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6796326 | 0.89 | EGFR (0.71) | EGFRERBB2GAKRIPK2BUB1 | |
| SCHEMBL13285619 | 0.86 | EGFR (0.72) | EGFRERBB2GAKRIPK2BUB1 | |
| SCHEMBL6795102 | 0.85 | EGFR (1.00) | EGFRERBB2ABL1PDGFRBSRC | |
| SCHEMBL6794377 | 0.85 | EGFR (0.78) | EGFRERBB2GAKABCG2ABL1 | |
| SCHEMBL6794722 | 0.85 | EGFR (1.00) | EGFRERBB2ABL1LMNARAF1 | |
| SCHEMBL20865234 | 0.79 | EGFR (1.00) | EGFRGAKRIPK2BUB1STK10 | |
| SCHEMBL1507604 | 0.79 | EGFR (0.87) | EGFRERBB2GAKRIPK2BUB1 | |
| SCHEMBL2464248 | 0.79 | EGFR (0.82) | EGFRERBB2GAKRIPK2BUB1 | |
| Hydrochloric Acid SCHEMBL1507697 | 0.78 | EGFR (0.85) | EGFRERBB2GAKRIPK2BUB1 | |
| SCHEMBL667895 | 0.78 | EGFR (1.00) | EGFRERBB2GAKRIPK2BUB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6835735-B2 | Anticancer, tyrosine kinase inhibitors | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2004-12-28 | — | — | US | disclosed |
| US-20030045537-A1 | 4-(Phenylamino)-[1,4]dioxano[2,3-g]quinazoline derivatives and process for preparing the same | KOREAN INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045537-A1 | 4-(Phenylamino)-[1,4]dioxano[2,3-g]quinazoline derivatives and process for preparing the same | EGFR, ERBB2, ERBB4 | EGFR 1/4885ERBB2 2/4885GAK 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.